CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties.
Int J Nanomedicine. 2019 May 23;14:3819-3830. doi: 10.2147/IJN.S139450. eCollection 2019.
Int J Nanomedicine. 2019.
PMID: 31213803
Free PMC article.
Review.
In contrast, CPX-351 (Vyxeos) is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that was rationally designed to improve efficacy over the traditional 7+3 cytarabine/daunorubicin chemotherapy regimen for patients with acute myeloid leukemia (AML). …
In contrast, CPX-351 (Vyxeos) is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that was rationally designed to i …